EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis

Aumolertinib is a novel third-generation epidermal growth factor receptor (EGFR)-targeted oral tyrosine kinase inhibitor (TKIs). The positive phase III trial (AENEAS) reported objective response rate (ORR) was 73.8% and medium progression-free survival (mPFS) was 19.3 months which aumolertinib as 1st line treatment of patients with EGFR mutation Non-Small Cell Lung Cancer (NSCLC). An improved efficacy of the combination of first-generation EGFR-TKI and carboplatin plus pemetrexed was confirmed in NEJ009 study.